LFCR

LIFECORE BIOMEDICAL, INC. \DE\
7 filings tracked
healthcarebiotechnologySMALL ($300M-2B)

Signal Magnitude Chart

BEARISH | 80% | 5/6/2026 | earnings missBEARISH | 60% | 5/6/2026 | margin compressionNEUTRAL | 40% | 5/6/2026 | debt restructureBULLISH | 90% | 5/6/2026 | regulatory actionBEARISH | 80% | 5/6/2026 | earnings missBEARISH | 60% | 5/6/2026 | margin compressionNEUTRAL | 40% | 5/6/2026 | debt restructureBULLISH | 90% | 5/6/2026 | regulatory actionBEARISH | 80% | 5/6/2026 | earnings missBEARISH | 60% | 5/6/2026 | margin compressionNEUTRAL | 40% | 5/6/2026 | debt restructureBULLISH | 90% | 5/6/2026 | regulatory actionBEARISH | 80% | 5/6/2026 | earnings missBEARISH | 60% | 5/6/2026 | margin compressionNEUTRAL | 40% | 5/6/2026 | debt restructureBULLISH | 90% | 5/6/2026 | regulatory actionBEARISH | 80% | 5/6/2026 | earnings missBEARISH | 60% | 5/6/2026 | margin compressionNEUTRAL | 40% | 5/6/2026 | debt restructureBULLISH | 90% | 5/6/2026 | regulatory actionBEARISH | 80% | 5/6/2026 | earnings missBEARISH | 60% | 5/6/2026 | margin compressionNEUTRAL | 40% | 5/6/2026 | debt restructureBULLISH | 90% | 5/6/2026 | regulatory actionBEARISH | 80% | 5/6/2026 | earnings missBEARISH | 60% | 5/6/2026 | margin compressionNEUTRAL | 40% | 5/6/2026 | debt restructureBULLISH | 90% | 5/6/2026 | regulatory actionMay 26May 26HIGHLOW
bullish
bearish
neutral

Signal Timeline

bearishMay 6

Total revenues declined 34% year-over-year to $23.2 million.

earnings miss
80%
bearishMay 6

Gross profit percentage dropped from 28.0% to 19.2%.

margin compression
60%
neutralMay 6

High-cost term loan with 20.9% effective interest rate remains the primary debt instrument.

debt restructure
40%
bullishMay 6

SEC concluded investigation with no action taken against the company.

regulatory action
90%
bearishMay 6

Total revenues declined 34% year-over-year to $23.2 million.

earnings miss
80%
bearishMay 6

Gross profit percentage dropped from 28.0% to 19.2%.

margin compression
60%
neutralMay 6

High-cost term loan with 20.9% effective interest rate remains the primary debt instrument.

debt restructure
40%
bullishMay 6

SEC concluded investigation with no action taken against the company.

regulatory action
90%
bearishMay 6

Total revenues declined 34% year-over-year to $23.2 million.

earnings miss
80%
bearishMay 6

Gross profit percentage dropped from 28.0% to 19.2%.

margin compression
60%
neutralMay 6

High-cost term loan with 20.9% effective interest rate remains the primary debt instrument.

debt restructure
40%
bullishMay 6

SEC concluded investigation with no action taken against the company.

regulatory action
90%
bearishMay 6

Total revenues declined 34% year-over-year to $23.2 million.

earnings miss
80%
bearishMay 6

Gross profit percentage dropped from 28.0% to 19.2%.

margin compression
60%
neutralMay 6

High-cost term loan with 20.9% effective interest rate remains the primary debt instrument.

debt restructure
40%
bullishMay 6

SEC concluded investigation with no action taken against the company.

regulatory action
90%
bearishMay 6

Total revenues declined 34% year-over-year to $23.2 million.

earnings miss
80%
bearishMay 6

Gross profit percentage dropped from 28.0% to 19.2%.

margin compression
60%
neutralMay 6

High-cost term loan with 20.9% effective interest rate remains the primary debt instrument.

debt restructure
40%
bullishMay 6

SEC concluded investigation with no action taken against the company.

regulatory action
90%
bearishMay 6

Total revenues declined 34% year-over-year to $23.2 million.

earnings miss
80%
bearishMay 6

Gross profit percentage dropped from 28.0% to 19.2%.

margin compression
60%
neutralMay 6

High-cost term loan with 20.9% effective interest rate remains the primary debt instrument.

debt restructure
40%
bullishMay 6

SEC concluded investigation with no action taken against the company.

regulatory action
90%
bearishMay 6

Total revenues declined 34% year-over-year to $23.2 million.

earnings miss
80%
bearishMay 6

Gross profit percentage dropped from 28.0% to 19.2%.

margin compression
60%
neutralMay 6

High-cost term loan with 20.9% effective interest rate remains the primary debt instrument.

debt restructure
40%
bullishMay 6

SEC concluded investigation with no action taken against the company.

regulatory action
90%